Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zeneca Zomig

Executive Summary

Zeneca journal ad comparing migraine therapy zolmitriptan to Glaxo Wellcome's Imitrex (sumatriptan) is in breach of the Association of British Pharmaceutical Industry's Code of Practice, the Prescription Medicines Code of Practice Authority panel finds in its most recent report on advertising reviews. The ad is headed by the statement "WOW!" followed by, "In migraine, Zomig 2.5 mg is significantly more effective than sumatriptan 50 mg for headache response at two and four hours." The data show that Zomig and Imitrex response rates at two and four hours were 67% vs. 64% and 83% vs. 81%, respectively. The panel accepted that Zomig data showed a statistically significant greater response than Imitrex, which "might be clinically relevant." However, use of word "WOW" implies that readers would notice "large clinical difference" between Zomig and Imitrex
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel